• The Korean Journal of Zoology
• /
• v.35 no.2
• /
• pp.173-182
• /
• 1992

흰쥐에 Spirometro rrinoce측 제3기 유충(고충 sparganum)이 감염되었을때 유충에서 생성된 성장호르몬 유사물질이 흰쥐 성장에 미치는 영향을 조사하기 위하여, 감염 기일이 경과에 따라 흰쥐의 뇌하수체와 유충의 체내에서 성장호르몬 분비세포를 면역조직화학염색으로 검색하였다. 유충의 표피와 표피성 근육층 및 근질 근육층에서 면역반응성을 띄는 성장 호르몬이 동정되었으며 감염시기의 경과에 따라 성장호르몬 분비세포의 수가 점차 증가하였다. 이와는 대조적으로 흰쥐의 뇌하수체에서는 성장호르몬 분비세포의 수가 감염 기일의 경과에 따라 정상대조군에 비하여 점차 감소 하였으며, 감염후 3개월이 경과되면 다시 증가하여 정상대조군의 수준으로 회복되었다. 또한 유충에 감염된 기일의 경과에 따른 횐쥐의 혈중 성장호르몬 농도변화를 dot-ELISA 방법으로 추정한 결깍 정상대조군의 성장호르몬의 양과 유의한 차이는 없었다. 결론적으로 유충의 체내에서 생성된 성장호르몬 유사물질이 전이숙주인 흰쥐의 성장을 유도할 것으로 사료된다.

• The Monthly Diabetes
• /
• s.287
• /
• pp.10-14
• /
• 2013

인터넷을 열어 무심코 '성장호르몬과 당뇨병'이란 단어를 검색해 보면 주로 '성장호르몬이 당뇨병 위험도를 높인다'라는 식의 부정적인 자료들을 주로 접하게 된다. 하지만 내용들을 찬찬히 살펴보다 보면 '성장호르몬이 노인에서 삶의 질을 증진시키고 노화를 방지하는 치료제로 사용된다'는 자료들도 간간히 찾아볼 수 있는데 우리는 이 대목에서 성장호르몬이 좋다는 것인지 아니면 나쁘니 절대 사용하지 말라는 것인지 혼란이 생긴다. 따라서 본 원고에서는 성장호르몬의 역할과 임상 적용시 나타나는 장점 및 단점, 특히 당뇨병과의 연관성에 대해 살펴보고자 한다.

• Journal of the korean veterinary medical association
• /
• v.39 no.4
• /
• pp.351-360
• /
• 2003

성장촉진용 호르몬제제는 생체에서 근육단백질 합성 증가, 성장촉진 효과를 발휘하는 생리활성 물질로 정상적인 분비과정을 통하여 생성되는 천연호르몬과 화학적으로 제조된 합성호르몬으로 대별된다. 주요 육류수출국에서는 가축의 생산성 향상을 목적으로 성장촉진용 호르몬제제의 불법적인 오$\cdot$남용이 성행하여 식육중에 잔류되는 문제를 일으키고 있다. 축산물중 성장촉진용 호르몬 제제의 잔류방지를 위해서는 축산현장에서 사용되는 동물용 의약품의 용법, 용량을 정확히 지키고 휴약기간을 준수하는 자세가 관건이며 이를 위하여 수의사의 적극적인 계도와 홍보가 절실히 필요하다.

• Clinical and Experimental Pediatrics
• /
• v.52 no.8
• /
• pp.922-929
• /
• 2009

Purpose : The aim was to investigate the clinical characteristics and responses to growth hormone (GH) therapy in children with attenuated growth who showed normal GH responses to GH stimulation tests (GHST). Methods : The study included 39 patients with height velocity (HV) of less than 4 cm/yr and normal GHST results. Clinical characteristics of patients were analyzed retrospectively. Results : Eleven were born as small for gestational age (SGA) and 28 as appropriate for age (AGA). In the SGA group, the standard deviation score (SDS) of age and height measured at their first visit was significantly low. Sixteen patients were treated with GH and six of 23 without GH therapy were followed for 1 year after GHST. The mean (range) of HV was 7.7 (4.9 to 11.1) cm/yr in patients with GH therapy and 3.7 (2.7 to 4.5) cm/yr in those without GH therapy, which was statistically significant (P<0.001). In the GH-treated group, HV and difference in height SDS during the treatment increased significantly (P<0.001; P< 0.001, respectively). HV increased after 1 year of GH therapy in the SGA and AGA groups (SGA, P=0.043; AGA, P=0.003). The level of Insulin-like growth factor-I was significantly lower in GH-treated patients with height SDS <-3 than those with ${\geq}3$ (P=0.023). Conclusion : In children with growth failure and normal GHST, HV increases significantly by short-term GH therapy. The assessment of long-term effects of GH therapy is necessary. Moreover, further studies should be considered to evaluate the GH-IGF-I axis due to the possibility of GH insensitivity syndrome.

• Development and Reproduction
• /
• v.4 no.2
• /
• pp.221-229
• /
• 2000

Lactogenesis in mammary gland is under the control of various lactogenic hormones including hypophysial growth hormone and prolactin. Recent studies reported that such pituitary lactogenic hormones are also expressed in mammary cells as well as in pituitary. For the purpose to analyze the role of these non-pituitary hormones in mammary cells, $\beta$ -lactoglobulin (BLG) gene promoter was selected as a model system. The growth hormone suppressed BLG promoter activity when it was applied alone on cultured mammary HCll cells. Along with lactogenic hormones such as insulin, prolactin and glucocorticoid, however, it significantly enhanced expression of BLG promoter activity in a dosage- dependent manner. Exogenous expression of the growth hormone gene in cultured mammary cells also strongly promoted cell proliferation and BLG promoter activity. Bovine growth hormone promoter, on the contrary, did not revealed any notable activity. Above results suggest that endogenous expression of the pituitary hormone genes in mammary cells is not a regulation leakage but a physiological control. Moreover, artificial overproduction of the growth hormone in mammary gland may help increase milk production.

• Korean Journal of Applied Biomechanics
• /
• v.18 no.1
• /
• pp.235-243
• /
• 2008

The purpose of this study is to find out the effect of Growth Hormone promotin and kinetic factors on Growth Hormone Activated Shoes. The results of the present study were as follows; First, there was a significient difference between a normal shoes and the Growth Hormone activated shoes in the student's GH secretion with running test, and there was a significant interaction effect between shoes and distance. therefore it can be assumed that there is a significant effect of GH secretion in student at growth period during running with Growth Hormine Activated Shoes. Second, Within 4km walking, Growth Hormone secretion was in creased averagely in student. Third, Growth Hormone Activated Shoes make a large load for light motion as walking. For heavy motion as running, it make a large impulsion but good pressure distribution and small loading rate.

• Korean Journal of Animal Reproduction
• /
• v.18 no.3
• /
• pp.175-182
• /
• 1994

Rat $\beta$-casein 유전자와 사람 성장호르몬 (hGH) 유전자의 융합유전자를 생쥐 수정란의 웅성전핵에 미세주입하여 형질전환생쥐 (transgenic mouse) 6계통을 확립하였다. 이들로부터 사람성장호르몬(hGH) 유전자의 발현 여부를 조사한 결과, 6계통중 4계통의 생쥐 유즙에서 hGH가 2~900 ng/ml 수준으로 발현되고 있었으며, 혈중에서는 hGH가 검출되지 않았다. 따라서 이들 형질전환생쥐에서 사람성장호르몬이 우선특이적으로 발현, 분비되고 있음을 알 수 있었다. 한편, 사람성장호르몬의 발현이 확인된 두 계통 (ChGH2-2, CChGH2)의 형질전환생쥐를 대상으로 하여 세대별, 산차별로 유즙내 사람성장호르몬의 함량을 조사한 결과, 3세대에 걸쳐, 또한 제1세대에서의 세차례 반복된 비유기에도 유즙내 사람성장호르몬은 지속적으로 분비되고 있었다. 이상의 결과는 형질전환생쥐에서의 외래유전자의 발현성은 반복되는 비유기와 여러 세대에 걸쳐 안정적으로 유지됨을 보여 주고 있다.

• Clinical and Experimental Pediatrics
• /
• v.48 no.8
• /
• pp.865-870
• /
• 2005

Purpose : The use of growth hormone(GH) to promote growth in normal short children without classical GH deficiency is controversial. Numerous foreign studies have shown the effects of GH therapy in children with idiopathic short stature(ISS) whereas few has been interested in Korea. Therefore, this study is designed to investigate the effects of GH therapy on ISS by observing correlations and changes among various growth parameters such as, insulin-like growth factor-I(IGF-I) and insulin-like growth factor binding protein-3(IGFBP-3). Methods : This study was conducted retrospectively with 15 children with ISS in Chungbuk National University Hospital in Korea. Mean age was $11.44{\pm}2.81$ and the children were treated with 0.66 IU/kg/wk dosage of GH for 1 or 2 years. Also, the growth parameters before and after the GH therapy were observed. Results : Height standard deviation score(HT-SDS) was increased from $-1.85{\pm}0.70$ to $-1.58{\pm}0.56$ at 1 year and to $-1.21{\pm}0.37$ at 2 years after GH therapy. Predicted adult height standard deviation score(PAH-SDS) was also increased from $-2.10{\pm}0.52$ to $-1.67{\pm}0.59$ at 1 year, and to $-0.96{\pm}0.60$ at 2 years. Serum IGF-I and IGFBP-3 levels were significantly increased after 1 year and marginally increased after 2 years of GH therapy. Conclusion : It is concluded that GH therapy has growth promoting effect. The significant increase in IGF-I and IGFBP-3 levels during the GH therapy suggests that IGF-I and IGFBP-3 are useful predictors of response to the use of GH therapy. It is expected that larger patient samples would provide more reliable information about the effect of GH therapy.

• Korean Journal of Animal Reproduction
• /
• v.25 no.4
• /
• pp.381-388
• /
• 2001

The present study was designed to obtain porcine growth hormone binding protein (pGHBP) improved biological activation as derived mutation in binding site with growth horlnone (GH). A 756 bp of fragment encoding the extracellular domain of pGHBP gene was cloned from the total RNA of porcine fat tissue by reverse transcriptase polymerase chain reaction (RT-PCR) and created mutation in positions 26 and 122 using site-directed mutagenesis method. Position 26 is one and it is near to get on five potential N-linked glycosylation sites located in the extracellular domain of porcine growth hormone receptor known to have a direct influence on combination with GH. Position 122 is known as one of conformational epitope in bovine. It was over-expressed in E. coli using pET-32(c) expression vector and precisely purified by S-protein agarose and enterokinase. In our results, we was obtained pmGHBP of 30 kDa. It suggests to study the effects of the pmGHBP on cell proliferation in vitro and growth rate in vivo after administration.

• Clinical and Experimental Pediatrics
• /
• v.46 no.3
• /
• pp.277-283
• /
• 2003

Purpose : Craniopharyngiomas are often accompanied by severe endocrine disorders. Although there is universal growth hormone deficiency(GHD), the resulting growth pattern is very heterogeneous. We report the growth and endocrine outcome of 44 children with craniopharyngioma, with emphasis on initial symptoms, growth before and during growth hormone(GH) treatment and spontaneous growth in spite of GHD. Methods : We performed a retrospective study of 44 children treated at our centre between 1984 and 2002. Results : About 30% of patients had symptoms suggesting endocrine disorder at diagnosis. After surgery, multiple endocrinopathies were almost universal. Before GH therapy, height velocity was $8.00{\pm}2.71cm/yr$ in the normal growth group(n=11) and $1.79{\pm}1.10cm/yr$ in the subnormal growth group(n=7) during the first year and during the second year, $6.76{\pm}2.49cm/yr$ and $2.29{\pm}1.33cm/yr$, respectively. There was no difference of body mass index(BMI) change between before and after surgery in the two groups. Height standard deviation score(SDS) was $-1.46{\pm}0.74$ in the normal growth group and $-0.43{\pm}0.97$ in the subnormal growth group. Before GH treatment height SDS was $-1.31{\pm}1.25$ and BMI was $20.46{\pm}3.60$. During GH treatment, height SDS increased to $-0.60{\pm}1.37$ in the first, and to $-0.41{\pm}1.54$ in the second year(P<0.05), but BMI did not change significantly. Conclusion : The endocrine morbidity could develop in most children with craniopharyngioma before and after the operation and should be managed properly. Although all treated patients benefit from GH therapy, further studies are necessary to find out the possible mechanism of growth regulation in normally growing children, despite GH deficient.